|
Founded in 1999, the Company is focusing on the unmet needs of healthcare and life science industry. Aviva has pioneered cell-based platforms,
which have led to an innovative product (SealChip™) which has become the industry standard for ion channel-focused drug discovery.
Aviva has developed innovative rare cell enrichment technologies, particularly focused on circulating tumor cells (CTC), which can significantly
advance the accuracy and sensitivity of cancer disease diagnosis and monitoring. The Company continues to leverage its expertise in cell-based
assays by targeting new commercial applications and services which will benefit patients and pharmaceutical development.
|
|
| |
AVIVA has been in the ion channel field since 2001, launched its (SealChip™) product in 2003, which initiated hERG screening service in 2004.
Since then we have strived to continually increase our offerings including launching EPOD™ service in 2006 and, in 2008, safety screening
against various cardiovascular models including human tissue assays. In 2010 we launched our custom cell line services. |
| |
|
| |
|
|
